Dalbavancin is a type of antibiotic used to treat skin infections caused by bacteria. It belongs to a class of antibiotics called lipoglycopeptides, which work by stopping bacteria from making the proteins needed for them to multiply and grow. Dalbavancin is used to treat skin and skin structure infections caused by certain bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is usually given as an intravenous (IV) injection in a healthcare setting. Possible side effects of Dalbavancin include nausea, vomiting, diarrhea, and headache.
Dalbavancin is a prescription antibiotic medication sold under the brand names Dalvance (in the US) and Xydalba (in the EU) . It belongs to a class of drugs called lipoglycopeptides, which are powerful antibiotics used to treat serious infections caused by certain types of bacteria.
Dalbavancin is specifically approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) [1]. MRSA infections are becoming increasingly common and can be difficult to treat because the bacteria are resistant to many other antibiotics.
Dalbavancin is a long-lasting antibiotic due to its prolonged half-life (14.4 days), high protein binding capacity, and intense tissue penetration [2]. This means that it can be given less frequently than other antibiotics, typically only once or twice during the course of treatment. This can be beneficial for patients who have difficulty taking medication regularly or who have difficulty with intravenous (IV) access.